Vancomycin Trough Monitoring Protocol

Introduction to Vancomycin Monitoring

The American College of Clinical Pharmacology and Infectious Diseases specialists recommend obtaining the initial vancomycin trough level immediately before the fourth dose to ensure steady-state conditions have been reached 1, 2
Steady-state achievement is variable but occurs approximately just before the fourth dose, with trough serum concentrations being the most accurate and practical method of monitoring vancomycin effectiveness 1

For complicated or serious infections, such as bacteremia, endocarditis, osteomyelitis, meningitis, hospital-acquired pneumonia, and severe skin/soft tissue infections, target trough concentrations of 15-20 mg/L 1, 2, 3
This range is designed to achieve an AUC/MIC ratio ≥400 for most patients when MIC ≤1 mg/L, according to the Infectious Diseases Society of America 1, 2
For less severe infections, target trough concentrations of 10-15 mg/L 3

Trough monitoring is required for patients with morbid obesity, fluctuating volumes of distribution, and treatment duration >7 days, as recommended by the Clinical Pharmacology Society 2
Frequent monitoring is not recommended for short-course therapy (≤5 days) or lower-intensity dosing targeting troughs ≤15 mg/L, as stated by the American College of Clinical Pharmacology 1
When trough exceeds 20 mg/L, hold the next scheduled dose immediately and recheck the trough level before administering any subsequent doses, as advised by the Praxis Medical Insights 2, 3

For obese patients, calculate initial vancomycin dosages based on actual body weight, and subsequent dosage adjustments should be based on actual serum concentrations, according to the Clinical Infectious Diseases guidelines 1

Switch to alternative antibiotics when vancomycin MIC ≥2 mg/L, as target AUC/MIC ratios are not achievable with conventional dosing, as recommended by the Praxis Medical Insights 2, 3
Continuing the same dosage despite elevated trough levels increases nephrotoxicity risk, and monitoring only peak levels provides no clinical benefit, as warned by the Clinical Pharmacology Society 2, 3